Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography

被引:66
作者
Krul, C [1 ]
Hageman, G [1 ]
机构
[1] Univ Maastricht, Dept Hlth Risk Anal & Toxicol, NL-6200 MD Maastricht, Netherlands
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 1998年 / 709卷 / 01期
关键词
enzymes; caffeine; paraxanthine; 1,7-dimethylurate; 1-methylxanthine; 1-methylurate; 5-acetylamino-6-formylamino-3-methyluracil;
D O I
10.1016/S0378-4347(98)00016-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An isocratic high-performance liquid chromatography procedure was developed for the analysis of five urinary metabolites of caffeine; caffeine or 1,3,7-trimethylxanthine (137X), paraxanthine or 1,7-dimethylxanthine (17X), 1,7-dimethylurate (17U), 1-methylxanthine (1X), 1-methylurate (1U) and 5-acetylamino-6-formylamino-3-methyluraci (AFMU). A standardized procedure was used for oral intake of caffeine and for urine collection. Conditions for sample storage and preparation were optimized, resulting in no detectable loss of caffeine metabolites after storage of the urine samples for four months. Urine samples were extracted with chloroform-2-propanol (4:1, v/v) and separated on a reversed-phase column with acetic acid (33%)-tetrahydrofuran-acetonitrile-water (1:2.5:44:925.5, v/v) as the eluent. Peaks were monitored at 280 nm. Peak heights were measured and the five metabolites were quantified using calibration curves. Cytochrome P4501A2 (CYP1A2) activity was calculated from the molar ratio (AFMU+1X+1U)/17U, N-acetyltransferase (NAT) from the ratio AFMU/1X, XO from the ratio 1U/1X+1U and cytochrome P4502A6 (CYP2A6) from the ratio 17U/(17U+17X+1U+1X+AFMU). The inter-assay coefficients of variation ranged from 1.7% for 17U to 5.7% for 1X. The intra-individual variation in metabolite ratios determined in two people, with intervals of a few days to several weeks between measurements, ranged from 2.1% for XO to 11.0% for CYP2A6. Using this procedure, metabolic ratios were determined for four groups of subjects; healthy, non-smoking females using oral contraceptives (OC users, n=5) and non-users (n=5), healthy nonsmoking males (n=9) and children (n=7). Results found in this study were comparable to results reported in the literature for subjects with similar characteristics. A significantly higher CYP1A2 ratio was found for males (4.87+/-0.47) compared to females (3.62+/-0.91; p=0.005, Mann-Whitney). For the other enzyme activities, no significant differences were found between the groups of subjects in this study. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 18 条
[1]  
BOLOGA M, 1991, J PHARMACOL EXP THER, V257, P735
[2]   DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES [J].
BUTLER, MA ;
LANG, NP ;
YOUNG, JF ;
CAPORASO, NE ;
VINEIS, P ;
HAYES, RB ;
TEITEL, CH ;
MASSENGILL, JP ;
LAWSEN, MF ;
KADLUBAR, FF .
PHARMACOGENETICS, 1992, 2 (03) :116-127
[3]   A URINARY METABOLITE RATIO THAT REFLECTS SYSTEMIC CAFFEINE CLEARANCE [J].
CAMPBELL, ME ;
SPIELBERG, SP ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (02) :157-165
[4]   CAFFEINE METABOLISM IN A HEALTHY SPANISH POPULATION - N-ACETYLATOR PHENOTYPE AND OXIDATION PATHWAYS [J].
CARRILLO, JA ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (03) :293-304
[5]   GENETICALLY-DETERMINED DIFFERENCES IN DRUG-METABOLISM AS A RISK FACTOR IN DRUG TOXICITY [J].
EICHELBAUM, M ;
KROEMER, HK ;
MIKUS, G .
TOXICOLOGY LETTERS, 1992, 64-5 :115-122
[6]   VARIABILITY IN CAFFEINE METABOLISM [J].
GRANT, DM ;
TANG, BK ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (05) :591-602
[7]  
HORN EP, 1995, CANCER EPIDEM BIOMAR, V4, P529
[8]  
KADLUBAR FF, 1990, PROG CLIN BIOL RES, V340, P107
[9]   THE USE OF CAFFEINE FOR ENZYME ASSAYS - A CRITICAL-APPRAISAL [J].
KALOW, W ;
TANG, BK .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (05) :503-514
[10]   LOW CYP1A2 ACTIVITY IN RURAL SHONA CHILDREN OF ZIMBABWE [J].
MASIMIREMBWA, CM ;
BEKE, M ;
HASLER, JA ;
TANG, BK ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (01) :25-31